As IVLBCL is considered a type of DLBCL, and immunohistochemistry, namely CD5+, CD30+, P53+, C-MYC+, and C-MYC/BCL2 double expression have been utilized as poor prognostic prediction in DLBCL, NOS, [15] concurrent expression of C-MYC/BCL2 defined by ≥40% C-MYC+ and ≥50%-70% BCL2+ cells [3] has been documented as a poor prognostic factor [15], and some authors proposed that it is a more reliable method for predicting risk of DLBCL than cell-of-origin classification [29–32]. This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.